KevinMichaelAlexanderMD

Heart Failure & Transplantation

Physician

Dr. Alexander is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Advanced Heart Failure and Transplant Cardiology, 2018 - 2019
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2014 - 2017
Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
Perelman School of Medicine at the University of PennsylvaniaClass of 2011

HI State Medical License 2022 - 2026
CA State Medical License 2018 - 2025
MA State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
American Board of Internal Medicine Cardiovascular Disease

PubMed

1 citations
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
Daniel P Judge, Kevin M Alexander, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia
Journal of the American College of Cardiology. 2025-03-18
Race, Genetics, and Social Determinants of Health in Transthyretin Cardiac Amyloidosis: A Literature Review and Call to Action.
Gracia Fahed, Briana N Collins, Nixuan Cai, John Isaiah Jimenez, Hiroki Kitakata
Current Cardiology Reports. 2025-03-05
2 citations
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Daniel P Judge, Julian D Gillmore, Kevin M Alexander, Amrut V Ambardekar, Francesco Cappelli
Circulation. 2025-03-04

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CMMarch 31st, 2025
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29th, 2024
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingMay 25th, 2024
Join now to see all